View Future GrowthChemoMetec 과거 순이익 실적과거 기준 점검 3/6ChemoMetec은 연평균 11.1%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 수입이 4.4% 증가했습니다. 매출은 연평균 10%의 비율로 증가했습니다. ChemoMetec의 자기자본이익률은 27.1%이고 순이익률은 35.9%입니다.핵심 정보11.13%순이익 성장률11.13%주당순이익(EPS) 성장률Life Sciences 산업 성장률26.83%매출 성장률10.00%자기자본이익률27.13%순이익률35.90%다음 순이익 업데이트10 Sep 2026최근 과거 실적 업데이트공시 • Jul 03+ 1 more updateChemoMetec A/S to Report Fiscal Year 2027 Results on Sep 09, 2027ChemoMetec A/S announced that they will report fiscal year 2027 results on Sep 09, 2027Reported Earnings • Sep 12Full year 2024 earnings released: EPS: kr.7.83 (vs kr.10.27 in FY 2023)Full year 2024 results: EPS: kr.7.83 (down from kr.10.27 in FY 2023). Revenue: kr.407.9m (down 8.2% from FY 2023). Net income: kr.136.3m (down 24% from FY 2023). Profit margin: 33% (down from 40% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.공시 • Aug 26+ 3 more updatesChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025ChemoMetec A/S announced that they will report fiscal year 2025 results on Sep 11, 2025Reported Earnings • Feb 07First half 2024 earnings released: EPS: kr.4.05 (vs kr.6.06 in 1H 2023)First half 2024 results: EPS: kr.4.05 (down from kr.6.06 in 1H 2023). Revenue: kr.199.8m (down 18% from 1H 2023). Net income: kr.70.6m (down 33% from 1H 2023). Profit margin: 35% (down from 43% in 1H 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 14Full year 2023 earnings released: EPS: kr.10.27 (vs kr.9.16 in FY 2022)Full year 2023 results: EPS: kr.10.27 (up from kr.9.16 in FY 2022). Revenue: kr.444.4m (up 3.7% from FY 2022). Net income: kr.178.7m (up 12% from FY 2022). Profit margin: 40% (up from 37% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.공시 • Jun 28+ 4 more updatesChemoMetec A/S to Report Fiscal Year 2024 Results on Sep 11, 2024ChemoMetec A/S announced that they will report fiscal year 2024 results on Sep 11, 2024모든 업데이트 보기Recent updates공시 • Jul 03+ 1 more updateChemoMetec A/S to Report Fiscal Year 2027 Results on Sep 09, 2027ChemoMetec A/S announced that they will report fiscal year 2027 results on Sep 09, 2027Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Chairman Niels Thestrup was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • May 16ChemoMetec A/S, Annual General Meeting, Oct 08, 2026ChemoMetec A/S, Annual General Meeting, Oct 08, 2026.공시 • May 06Chemometec A/S Upgrades Earnings Guidance for the Financial Year 2025/2026ChemoMetec A/S upgraded earnings guidance for the financial year 2025/2026. For the year, the Company now expects revenue in the DKK 505 million - DKK 525 million range, up from DKK 490 million - DKK 520 million in the most recent guidance. To ensure continued compliance with the applicable accounting framework (IFRS), ChemoMetec has adjusted the allocation of revenue between instruments and services.공시 • Mar 26ChemoMetec A/S Revises Earnings Guidance for the Year 2025/2026ChemoMetec A/S revised earnings guidance for the year 2025/2026. For the year, the company expects revenue of DKK 490 million to DKK 520 million is now expected in the financial year 2025/26 against the most recently announced DKK 565 million to DKK 580 million.공시 • Feb 06Chemometec A/S Maintains Earnings Guidance for the Year 2025ChemoMetec A/S maintained earnings guidance for the year 2025. For the period, the company expects revenue in the range of DKK 565-580 million range.공시 • Oct 28ChemoMetec A/S Updates Earnings Guidance for the Year 2025-26ChemoMetec A/S updated earnings guidance for the year 2025-26. For the year, the company now expects revenue to be DKK 565 million - DKK 580 million against the most recently announced DKK 545 million- DKK 565 million. The company expects a positive trend in revenue and profit particularly in the last part of the financial year 2025/26.공시 • Oct 10ChemoMetec A/S Approves to Distribute DividendChemoMetec A/S at the AGM held on 9 October 2025, approved to distribute a dividend of DKK 7 per share of a nominal value of DKK 1.공시 • Sep 18ChemoMetec A/S, Annual General Meeting, Oct 09, 2025ChemoMetec A/S, Annual General Meeting, Oct 09, 2025, at 17:30 Romance Standard Time. Location: nordsjaellands konferencecenter, gydevang 39-41, 3450 allerod, Denmark공시 • Sep 13+ 3 more updatesChemometec A/S Provides Earnings Guidance for the Financial Year 2025/26ChemoMetec A/S provided earnings guidance for the financial year 2025/26. For the period, ChemoMetec expects revenue in the range of DKK 545 million-565 million (2024/25: DKK 495.6 million).공시 • Jan 10Chemometec A/S Updates Earnings Guidance for the 2024/2025 Financial YearChemoMetec A/S updated earnings guidance for the 2024/2025 Financial year. For the year, company expected revenue in the DKK 470 million - DKK 490 million range, up from DKK 460 million - DKK 475 million in the most recent guidance.공시 • Dec 04ChemoMetec A/S Updates Earnings Guidance for the Financial Year 2024-2025ChemoMetec A/S updated earnings guidance for the financial year 2024-2025. For the year, the company now expected revenue to be in the range of DKK 460 million to DKK 475 million, up from DKK 445 million to DKK 460 million in the most recent guidance.Recent Insider Transactions • Nov 13Deputy Chairman & Senior Advisor recently bought €428k worth of stockOn the 8th of November, Hans Glensbjerg bought around 7k shares on-market at roughly €61.17 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Hans has been a buyer over the last 12 months, purchasing a net total of €469k worth in shares.Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 27%After last week's 27% share price gain to €69.05, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €45.47 per share.Buy Or Sell Opportunity • Nov 12Now 52% overvalued after recent price riseOver the last 90 days, the stock has risen 38% to €69.05. The fair value is estimated to be €45.47, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.2% over the last 3 years. Earnings per share has grown by 8.7%. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.공시 • Nov 08ChemoMetec A/S Maintains Earnings Guidance for the Full-Year 2024-2025ChemoMetec A/S maintained earnings guidance for the full-year 2024-2025. For the year, the company expects revenue to be in the range of DKK 445 million to DKK 460 million.Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Chairman Niels Thestrup was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Oct 23ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA.ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA for €2.8 million on September 20, 2024. A cash consideration of €2.83 million will be paid by ChemoMetec A/S. As part of consideration, €2.83 million is paid towards common equity of Ovizio Imaging Systems NV/SA. For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million. ChemoMetec now has three weeks to carry out a due diligence, and if the outcome of this is positive, ChemoMetec will most likely proceed with the acquisition. The transaction is subject to approval of offer by target shareholders, consummation of due diligence investigation and definitive agreement. The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the remaining shareholders, who are under a legal obligation to accept. As of October 16, 2024, the deal has been approved by shareholders of Ovizio Imaging Systems NV/SA. Closing is expected to take place within the coming week and will coincide with the actual acquisition date. ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA on October 22, 2024.Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €58.40, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 28x in the Life Sciences industry in Europe. Total loss to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €32.01 per share.공시 • Oct 17ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025ChemoMetec A/S revised earnings guidance for the financial year 2024/2025. The company sustained its positive performance in the first quarter of 2024/2025 with better-than-expected sales and order intake. Based on this, the company now expects revenue for the 2024/2025 financial year in the DKK 445 million to DKK 460 million range, up from DKK 435 million to DKK 450 million in the most recent guidance.공시 • Oct 11ChemoMetec A/S Approves DividendChemoMetec A/S at its Annual General Meeting held on 10 October 2024, approved the proposal of the Board of Directors to distribute a dividend of DKK 4 per share of a nominal value of DKK 1.Upcoming Dividend • Oct 04Upcoming dividend of kr.4.00 per shareEligible shareholders must have bought the stock before 11 October 2024. Payment date: 15 October 2024. Payout ratio is a comfortable 51% but the company is paying out more than the cash it is generating. Trailing yield: 1.0%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (0.7%).공시 • Sep 21ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA.ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA on September 20, 2024. For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million. The transaction is subject to consummation of due diligence investigation.Declared Dividend • Sep 15Dividend of kr.4.00 announcedShareholders will receive a dividend of kr.4.00. Ex-date: 11th October 2024 Payment date: 15th October 2024 Dividend yield will be 7.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but not covered by cash flows (122% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Sep 12Full year 2024 earnings released: EPS: kr.7.83 (vs kr.10.27 in FY 2023)Full year 2024 results: EPS: kr.7.83 (down from kr.10.27 in FY 2023). Revenue: kr.407.9m (down 8.2% from FY 2023). Net income: kr.136.3m (down 24% from FY 2023). Profit margin: 33% (down from 40% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.공시 • Sep 12ChemoMetec A/S provides earnings guidance for the year 2024/25ChemoMetec A/S provided earnings guidance for the year 2024/25. For the period, the company expected revenue to be in the DKK 435 million to DKK 450 million range against DKK 407.4 million last year.공시 • Aug 26+ 3 more updatesChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025ChemoMetec A/S announced that they will report fiscal year 2025 results on Sep 11, 2025Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €48.04, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €32.31 per share.공시 • May 25ChemoMetec A/S Announces CFO ChangesThe board of ChemoMetec A/S appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY. The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen takes over. The board would like to thank Niels Høy Nielsen for his contribution to ChemoMetec and for the good cooperation. CEO Martin Helbo Behrens and CFO Kim Nicolajsen will hereafter form the executive management of ChemoMetec.Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €47.66, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €28.71 per share.Buy Or Sell Opportunity • Apr 17Now 24% overvaluedOver the last 90 days, the stock has fallen 16% to €41.12. The fair value is estimated to be €33.23, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 20% in the next 2 years.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €40.56, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €34.06 per share.공시 • Apr 13ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24ChemoMetec A/S provided earnings guidance for the year 2023/24. For the period, the company expected revenue to be in the DKK 400 million - DKK 415 million range against previously announced DKK 400 million - DKK 435 million and thus still within the most recently announced range.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €60.55, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 17% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €33.73 per share.공시 • Mar 13ChemoMetec A/S Announces CEO ChangesThe Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of March 13, 2024. The decision is based on the Board’s assessment that ChemoMetec in the current phase of the company's development needs a different composition of executive management skills. Therefore, the board has entered into an agreement with the company's current CEO Rasmus Kofoed to resign from his position as of March 13, 2024. Martin Helbo Behrens, who is 31 years old, has been employed at ChemoMetec for a number of years. He was originally employed as part of Group Finance, but in 2021 he relocated to the USA to take up a position as first COO and then CFO of ChemoMetec's American subsidiary. In these roles he has made a significant contribution to ChemoMetec's high growth and commercial success in the North American market over recent years. After almost three years in the USA, Martin Helbo Behrens returned to ChemoMetec's head office in Allerød as Deputy COO in 2023 and took up the position as COO on 1 February 2024. With Martin Helbo Behrens' in-depth insight into ChemoMetec's organization, products and markets, and based on the results he has contributed to creating in ChemoMetec, the Board is convinced that Martin Helbo Behrens will be the right profile to head ChemoMetec as CEO in the future. CEO Martin Helbo Behrens and CFO Niels Høy Nielsen will hereafter form the executive management of ChemoMetec.Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 32%After last week's 32% share price gain to €64.05, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 23x in the Life Sciences industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €34.40 per share.Reported Earnings • Feb 07First half 2024 earnings released: EPS: kr.4.05 (vs kr.6.06 in 1H 2023)First half 2024 results: EPS: kr.4.05 (down from kr.6.06 in 1H 2023). Revenue: kr.199.8m (down 18% from 1H 2023). Net income: kr.70.6m (down 33% from 1H 2023). Profit margin: 35% (down from 43% in 1H 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.공시 • Feb 06ChemoMetec A/S Maintains Earnings Guidance for the Year 2024ChemoMetec A/S maintained earnings guidance for the year 2024. The company maintain full-year guidance for 2023/24 of revenue in the range of DKK 400 million - DKK 435 million and EBITDA in the range of DKK 200 million - DKK 220 million.공시 • Dec 21ChemoMetec A/S Announces Executive ChangesChemoMetec A/S announced that COO and deputy chairman of the board Martin Glensbjerg has decided to step down in ChemoMetec to pass the baton on to the next generation. From 1 February 2024 until the end of 2024, he will act as Senior Advisor with reference to CEO Rasmus Kofoed. Martin Glensbjerg continues as deputy chairman of the board. In his new role, Martin Glensbjerg will, among other things, participate in the update of ChemoMetec's strategy and also contribute to ensuring a successful anchoring and launch of the upcoming new products, including XcytoMatic 40 and XcytoMatic 30. At the same time, Martin Helbo Behrens, Deputy COO, is appointed COO, and Bo Melholt Nielsen, Physicist & Project Manager, Chief R&D Officer. Both Martin Helbo Behrens and Bo Melholt Nielsen have been employed at ChemoMetec for a number of years. Before joining as Deputy COO earlier this year, Martin Helbo Behrens was CFO and COO in ChemoMetec's American subsidiary and was part of Group Finance before that. Bo Melholt Nielsen has a strong academic and professional background in physics, especially quantum optics, and as project manager for the development of XcytoMatic 40 and XcytoMatic 30 he has been a significant driving force behind the development of the new generation of products. Martin Glensbjerg was one of three co-founders when ChemoMetec was established in 1997, and since then he has held a leading position in the company and has made a significant contribution to ensuring that ChemoMetec has achieved an attractive global market position.Valuation Update With 7 Day Price Move • Dec 19Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €55.30, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 31x in the Life Sciences industry in Europe. Total loss to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €39.98 per share.Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 27%After last week's 27% share price gain to €43.46, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €41.87 per share.Buying Opportunity • Oct 25Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 41%. The fair value is estimated to be €45.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 37%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 13% per annum over the same time period.Valuation Update With 7 Day Price Move • Oct 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €45.84, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €44.40 per share.Upcoming Dividend • Oct 06Upcoming dividend of kr.6.00 per share at 1.8% yieldEligible shareholders must have bought the stock before 13 October 2023. Payment date: 17 October 2023. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (5.0%). Higher than average of industry peers (0.9%).공시 • Sep 14+ 1 more updateChemometec A/S Proposes Dividend for the 2022/23 Financial YearChemoMetec A/S proposed to the general meeting that a dividend of DKK 6.0 per share, equivalent to a total dividend payout of DKK 104.4 million, be distributed for the 2022/23 financial year. The proposal should be seen in the context of ChemoMetec’s strong financial position, and the planned investments in new facilities have also been taken into account.Reported Earnings • Sep 14Full year 2023 earnings released: EPS: kr.10.27 (vs kr.9.16 in FY 2022)Full year 2023 results: EPS: kr.10.27 (up from kr.9.16 in FY 2022). Revenue: kr.444.4m (up 3.7% from FY 2022). Net income: kr.178.7m (up 12% from FY 2022). Profit margin: 40% (up from 37% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.New Risk • Aug 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (7.0% average weekly change).공시 • Jun 28+ 4 more updatesChemoMetec A/S to Report Fiscal Year 2024 Results on Sep 11, 2024ChemoMetec A/S announced that they will report fiscal year 2024 results on Sep 11, 2024공시 • May 10ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023ChemoMetec A/S affirmed earnings guidance for the fiscal year 2022/2023. For the year, based on developments in the third quarter of 2022/23, guidance for financial year 2022/23, as announced in connection with the release of the interim report for 2022/23 on 8 February 2023, is maintained. Accordingly, revenue for 2022/23 is expected in the range of DKK 430 million - DKK 460 million.Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €52.90, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 36x in the Life Sciences industry in Europe. Total returns to shareholders of 29% over the past three years.Valuation Update With 7 Day Price Move • Feb 15Investor sentiment deteriorates as stock falls 25%After last week's 25% share price decline to €66.20, the stock trades at a trailing P/E ratio of 48.1x. Average trailing P/E is 45x in the Life Sciences industry in Europe. Total returns to shareholders of 76% over the past three years.Reported Earnings • Feb 10First half 2023 earnings released: EPS: kr.6.06 (vs kr.4.90 in 1H 2022)First half 2023 results: EPS: kr.6.06 (up from kr.4.90 in 1H 2022). Revenue: kr.242.7m (up 16% from 1H 2022). Net income: kr.105.4m (up 24% from 1H 2022). Profit margin: 43% (up from 41% in 1H 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 40% per year.공시 • Feb 09ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023ChemoMetec A/S updated earnings guidance for the fiscal year 2022/2023. For the year, the company expected revenue of DKK 430 million - DKK 460 million, against the previous guidance of DKK 485 million-DKK 505 million.Valuation Update With 7 Day Price Move • Dec 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €93.70, the stock trades at a trailing P/E ratio of 76.9x. Average trailing P/E is 42x in the Life Sciences industry in Europe. Total returns to shareholders of 267% over the past three years.공시 • Dec 15Chemometec A/S Announces Resignation of Steen Søndergaard as CEOSteen Søndergaard has announced that he wants to resign from his position as CEO of ChemoMetec A/S. It has been agreed that Steen Søndergaard remains in his position until a replacement has been found, however with resignation during the calendar year 2023 and possibly no later than 30 June 2023. The search for a new CEO has been initiated, and the Board of Directors expects to announce the name of the new CEO during the first quarter of 2023.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Nov 08ChemoMetec A/S Provides Earnings Guidance for the Financial Year 2022-23ChemoMetec A/S provided earnings guidance for the financial year 2022-23. For the period, the company expects revenue to be in the range of DKK 485 million - DKK 505 million.Valuation Update With 7 Day Price Move • Sep 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €79.50, the stock trades at a forward P/E ratio of 53x. Average forward P/E is 31x in the Life Sciences industry in Europe. Total returns to shareholders of 343% over the past three years.Reported Earnings • Sep 17Full year 2022 earnings released: EPS: kr.9.16 (vs kr.5.08 in FY 2021)Full year 2022 results: EPS: kr.9.16 (up from kr.5.08 in FY 2021). Revenue: kr.428.4m (up 52% from FY 2021). Net income: kr.159.5m (up 81% from FY 2021). Profit margin: 37% (up from 31% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.공시 • Sep 15ChemoMetec A/S Provides Revenue Guidance for the Fiscal Year 2023ChemoMetec A/S provided revenue guidance for the fiscal year 2023. For the period, the company expects revenue in the range of DKK 485 million - DKK 505 million.공시 • Jul 16+ 6 more updatesChemoMetec A/S, Annual General Meeting, Oct 12, 2023ChemoMetec A/S, Annual General Meeting, Oct 12, 2023.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 10First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: EPS: kr.4.90 (up from kr.2.43 in 1H 2021). Revenue: kr.209.8m (up 58% from 1H 2021). Net income: kr.85.2m (up 101% from 1H 2021). Profit margin: 41% (up from 32% in 1H 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 67% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Oct 08Upcoming dividend of kr.4.00 per shareEligible shareholders must have bought the stock before 15 October 2021. Payment date: 19 October 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (0.4%).Reported Earnings • Sep 18Full year 2021 earnings released: EPS kr.5.08 (vs kr.3.51 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: kr.281.1m (up 31% from FY 2020). Net income: kr.88.4m (up 49% from FY 2020). Profit margin: 31% (up from 28% in FY 2020). The increase in margin was driven by higher revenue.Is New 90 Day High Low • Feb 10New 90-day high: €80.40The company is up 48% from its price of €54.50 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 10.0% over the same period.Reported Earnings • Feb 07First half 2021 earnings released: EPS kr.2.43 (vs kr.1.68 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: kr.133.0m (up 28% from 1H 2020). Net income: kr.42.3m (up 54% from 1H 2020). Profit margin: 32% (up from 27% in 1H 2020). The increase in margin was driven by higher revenue.Is New 90 Day High Low • Dec 31New 90-day high: €76.60The company is up 37% from its price of €55.90 on 02 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 2.0% over the same period.Is New 90 Day High Low • Dec 16New 90-day high: €66.30The company is up 23% from its price of €54.00 on 17 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 1.0% over the same period.Is New 90 Day High Low • Dec 01New 90-day high: €60.70The company is up 14% from its price of €53.10 on 02 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 1.0% over the same period.Reported Earnings • Sep 19Full year earnings released - EPS €3.51Over the last 12 months the company has reported total profits of kr.59.2m, up 41% from the prior year. Total revenue was kr.214.1m over the last 12 months, up 22% from the prior year. Profit margins were 28%, which is higher than the 24% margin from last year. The increase in margin was driven by higher revenue.Is New 90 Day High Low • Sep 18New 90-day high: €54.00The company is up 26% from its price of €42.70 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 19% over the same period.매출 및 비용 세부 내역ChemoMetec가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:CHY 매출, 비용 및 순이익 (DKK Millions)날짜매출순이익일반관리비연구개발비31 Dec 25493177212030 Sep 25494182210030 Jun 25496186207031 Mar 25478178199031 Dec 24460169190030 Sep 24434153186030 Jun 24408136181031 Mar 24405140176031 Dec 23402144171030 Sep 23423161166030 Jun 23444179160031 Mar 23453179166031 Dec 22461180171030 Sep 22445170166030 Jun 22428159161031 Mar 22393145147031 Dec 21358131133030 Sep 21320110125030 Jun 2128188118031 Mar 2126281108031 Dec 202437498030 Sep 202296798030 Jun 202145997031 Mar 202065499031 Dec 1919748101030 Sep 191864598030 Jun 191764294031 Mar 191583786031 Dec 181413378030 Sep 181272574030 Jun 181131869031 Mar 181071569031 Dec 171021369030 Sep 17961066030 Jun 1790764031 Mar 1788661031 Dec 1685559030 Sep 1685854030 Jun 16851050031 Mar 16801147031 Dec 15751244030 Sep 156810420양질의 수익: CHY는 고품질 수익을 보유하고 있습니다.이익 마진 증가: CHY의 현재 순 이익률 (35.9%)은 지난해 (36.8%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: CHY의 수익은 지난 5년 동안 연평균 11.1% 증가했습니다.성장 가속화: 지난 1년간 CHY 의 수익 증가율(4.7%)은 5년 평균(연간 11.1%)보다 낮습니다.수익 대 산업: CHY의 지난 1년 수익 증가율(4.7%)은 Life Sciences 업계 평균(8.5%)을 능가하지 못했습니다.자기자본이익률높은 ROE: CHY의 자본 수익률(27.1%)은 높음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/09 20:18종가2026/07/09 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ChemoMetec A/S는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mads Brinkmann AndersenBerenbergKallum TitchmarshBofA Global ResearchSimon LarssonDanske Bank5명의 분석가 더 보기
공시 • Jul 03+ 1 more updateChemoMetec A/S to Report Fiscal Year 2027 Results on Sep 09, 2027ChemoMetec A/S announced that they will report fiscal year 2027 results on Sep 09, 2027
Reported Earnings • Sep 12Full year 2024 earnings released: EPS: kr.7.83 (vs kr.10.27 in FY 2023)Full year 2024 results: EPS: kr.7.83 (down from kr.10.27 in FY 2023). Revenue: kr.407.9m (down 8.2% from FY 2023). Net income: kr.136.3m (down 24% from FY 2023). Profit margin: 33% (down from 40% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
공시 • Aug 26+ 3 more updatesChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025ChemoMetec A/S announced that they will report fiscal year 2025 results on Sep 11, 2025
Reported Earnings • Feb 07First half 2024 earnings released: EPS: kr.4.05 (vs kr.6.06 in 1H 2023)First half 2024 results: EPS: kr.4.05 (down from kr.6.06 in 1H 2023). Revenue: kr.199.8m (down 18% from 1H 2023). Net income: kr.70.6m (down 33% from 1H 2023). Profit margin: 35% (down from 43% in 1H 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 14Full year 2023 earnings released: EPS: kr.10.27 (vs kr.9.16 in FY 2022)Full year 2023 results: EPS: kr.10.27 (up from kr.9.16 in FY 2022). Revenue: kr.444.4m (up 3.7% from FY 2022). Net income: kr.178.7m (up 12% from FY 2022). Profit margin: 40% (up from 37% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
공시 • Jun 28+ 4 more updatesChemoMetec A/S to Report Fiscal Year 2024 Results on Sep 11, 2024ChemoMetec A/S announced that they will report fiscal year 2024 results on Sep 11, 2024
공시 • Jul 03+ 1 more updateChemoMetec A/S to Report Fiscal Year 2027 Results on Sep 09, 2027ChemoMetec A/S announced that they will report fiscal year 2027 results on Sep 09, 2027
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Chairman Niels Thestrup was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • May 16ChemoMetec A/S, Annual General Meeting, Oct 08, 2026ChemoMetec A/S, Annual General Meeting, Oct 08, 2026.
공시 • May 06Chemometec A/S Upgrades Earnings Guidance for the Financial Year 2025/2026ChemoMetec A/S upgraded earnings guidance for the financial year 2025/2026. For the year, the Company now expects revenue in the DKK 505 million - DKK 525 million range, up from DKK 490 million - DKK 520 million in the most recent guidance. To ensure continued compliance with the applicable accounting framework (IFRS), ChemoMetec has adjusted the allocation of revenue between instruments and services.
공시 • Mar 26ChemoMetec A/S Revises Earnings Guidance for the Year 2025/2026ChemoMetec A/S revised earnings guidance for the year 2025/2026. For the year, the company expects revenue of DKK 490 million to DKK 520 million is now expected in the financial year 2025/26 against the most recently announced DKK 565 million to DKK 580 million.
공시 • Feb 06Chemometec A/S Maintains Earnings Guidance for the Year 2025ChemoMetec A/S maintained earnings guidance for the year 2025. For the period, the company expects revenue in the range of DKK 565-580 million range.
공시 • Oct 28ChemoMetec A/S Updates Earnings Guidance for the Year 2025-26ChemoMetec A/S updated earnings guidance for the year 2025-26. For the year, the company now expects revenue to be DKK 565 million - DKK 580 million against the most recently announced DKK 545 million- DKK 565 million. The company expects a positive trend in revenue and profit particularly in the last part of the financial year 2025/26.
공시 • Oct 10ChemoMetec A/S Approves to Distribute DividendChemoMetec A/S at the AGM held on 9 October 2025, approved to distribute a dividend of DKK 7 per share of a nominal value of DKK 1.
공시 • Sep 18ChemoMetec A/S, Annual General Meeting, Oct 09, 2025ChemoMetec A/S, Annual General Meeting, Oct 09, 2025, at 17:30 Romance Standard Time. Location: nordsjaellands konferencecenter, gydevang 39-41, 3450 allerod, Denmark
공시 • Sep 13+ 3 more updatesChemometec A/S Provides Earnings Guidance for the Financial Year 2025/26ChemoMetec A/S provided earnings guidance for the financial year 2025/26. For the period, ChemoMetec expects revenue in the range of DKK 545 million-565 million (2024/25: DKK 495.6 million).
공시 • Jan 10Chemometec A/S Updates Earnings Guidance for the 2024/2025 Financial YearChemoMetec A/S updated earnings guidance for the 2024/2025 Financial year. For the year, company expected revenue in the DKK 470 million - DKK 490 million range, up from DKK 460 million - DKK 475 million in the most recent guidance.
공시 • Dec 04ChemoMetec A/S Updates Earnings Guidance for the Financial Year 2024-2025ChemoMetec A/S updated earnings guidance for the financial year 2024-2025. For the year, the company now expected revenue to be in the range of DKK 460 million to DKK 475 million, up from DKK 445 million to DKK 460 million in the most recent guidance.
Recent Insider Transactions • Nov 13Deputy Chairman & Senior Advisor recently bought €428k worth of stockOn the 8th of November, Hans Glensbjerg bought around 7k shares on-market at roughly €61.17 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Hans has been a buyer over the last 12 months, purchasing a net total of €469k worth in shares.
Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 27%After last week's 27% share price gain to €69.05, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €45.47 per share.
Buy Or Sell Opportunity • Nov 12Now 52% overvalued after recent price riseOver the last 90 days, the stock has risen 38% to €69.05. The fair value is estimated to be €45.47, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.2% over the last 3 years. Earnings per share has grown by 8.7%. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.
공시 • Nov 08ChemoMetec A/S Maintains Earnings Guidance for the Full-Year 2024-2025ChemoMetec A/S maintained earnings guidance for the full-year 2024-2025. For the year, the company expects revenue to be in the range of DKK 445 million to DKK 460 million.
Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Chairman Niels Thestrup was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Oct 23ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA.ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA for €2.8 million on September 20, 2024. A cash consideration of €2.83 million will be paid by ChemoMetec A/S. As part of consideration, €2.83 million is paid towards common equity of Ovizio Imaging Systems NV/SA. For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million. ChemoMetec now has three weeks to carry out a due diligence, and if the outcome of this is positive, ChemoMetec will most likely proceed with the acquisition. The transaction is subject to approval of offer by target shareholders, consummation of due diligence investigation and definitive agreement. The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the remaining shareholders, who are under a legal obligation to accept. As of October 16, 2024, the deal has been approved by shareholders of Ovizio Imaging Systems NV/SA. Closing is expected to take place within the coming week and will coincide with the actual acquisition date. ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA on October 22, 2024.
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €58.40, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 28x in the Life Sciences industry in Europe. Total loss to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €32.01 per share.
공시 • Oct 17ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025ChemoMetec A/S revised earnings guidance for the financial year 2024/2025. The company sustained its positive performance in the first quarter of 2024/2025 with better-than-expected sales and order intake. Based on this, the company now expects revenue for the 2024/2025 financial year in the DKK 445 million to DKK 460 million range, up from DKK 435 million to DKK 450 million in the most recent guidance.
공시 • Oct 11ChemoMetec A/S Approves DividendChemoMetec A/S at its Annual General Meeting held on 10 October 2024, approved the proposal of the Board of Directors to distribute a dividend of DKK 4 per share of a nominal value of DKK 1.
Upcoming Dividend • Oct 04Upcoming dividend of kr.4.00 per shareEligible shareholders must have bought the stock before 11 October 2024. Payment date: 15 October 2024. Payout ratio is a comfortable 51% but the company is paying out more than the cash it is generating. Trailing yield: 1.0%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (0.7%).
공시 • Sep 21ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA.ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA on September 20, 2024. For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million. The transaction is subject to consummation of due diligence investigation.
Declared Dividend • Sep 15Dividend of kr.4.00 announcedShareholders will receive a dividend of kr.4.00. Ex-date: 11th October 2024 Payment date: 15th October 2024 Dividend yield will be 7.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but not covered by cash flows (122% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Sep 12Full year 2024 earnings released: EPS: kr.7.83 (vs kr.10.27 in FY 2023)Full year 2024 results: EPS: kr.7.83 (down from kr.10.27 in FY 2023). Revenue: kr.407.9m (down 8.2% from FY 2023). Net income: kr.136.3m (down 24% from FY 2023). Profit margin: 33% (down from 40% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
공시 • Sep 12ChemoMetec A/S provides earnings guidance for the year 2024/25ChemoMetec A/S provided earnings guidance for the year 2024/25. For the period, the company expected revenue to be in the DKK 435 million to DKK 450 million range against DKK 407.4 million last year.
공시 • Aug 26+ 3 more updatesChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025ChemoMetec A/S announced that they will report fiscal year 2025 results on Sep 11, 2025
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €48.04, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €32.31 per share.
공시 • May 25ChemoMetec A/S Announces CFO ChangesThe board of ChemoMetec A/S appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY. The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen takes over. The board would like to thank Niels Høy Nielsen for his contribution to ChemoMetec and for the good cooperation. CEO Martin Helbo Behrens and CFO Kim Nicolajsen will hereafter form the executive management of ChemoMetec.
Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €47.66, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €28.71 per share.
Buy Or Sell Opportunity • Apr 17Now 24% overvaluedOver the last 90 days, the stock has fallen 16% to €41.12. The fair value is estimated to be €33.23, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 20% in the next 2 years.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €40.56, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €34.06 per share.
공시 • Apr 13ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24ChemoMetec A/S provided earnings guidance for the year 2023/24. For the period, the company expected revenue to be in the DKK 400 million - DKK 415 million range against previously announced DKK 400 million - DKK 435 million and thus still within the most recently announced range.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €60.55, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 17% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €33.73 per share.
공시 • Mar 13ChemoMetec A/S Announces CEO ChangesThe Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of March 13, 2024. The decision is based on the Board’s assessment that ChemoMetec in the current phase of the company's development needs a different composition of executive management skills. Therefore, the board has entered into an agreement with the company's current CEO Rasmus Kofoed to resign from his position as of March 13, 2024. Martin Helbo Behrens, who is 31 years old, has been employed at ChemoMetec for a number of years. He was originally employed as part of Group Finance, but in 2021 he relocated to the USA to take up a position as first COO and then CFO of ChemoMetec's American subsidiary. In these roles he has made a significant contribution to ChemoMetec's high growth and commercial success in the North American market over recent years. After almost three years in the USA, Martin Helbo Behrens returned to ChemoMetec's head office in Allerød as Deputy COO in 2023 and took up the position as COO on 1 February 2024. With Martin Helbo Behrens' in-depth insight into ChemoMetec's organization, products and markets, and based on the results he has contributed to creating in ChemoMetec, the Board is convinced that Martin Helbo Behrens will be the right profile to head ChemoMetec as CEO in the future. CEO Martin Helbo Behrens and CFO Niels Høy Nielsen will hereafter form the executive management of ChemoMetec.
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 32%After last week's 32% share price gain to €64.05, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 23x in the Life Sciences industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €34.40 per share.
Reported Earnings • Feb 07First half 2024 earnings released: EPS: kr.4.05 (vs kr.6.06 in 1H 2023)First half 2024 results: EPS: kr.4.05 (down from kr.6.06 in 1H 2023). Revenue: kr.199.8m (down 18% from 1H 2023). Net income: kr.70.6m (down 33% from 1H 2023). Profit margin: 35% (down from 43% in 1H 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
공시 • Feb 06ChemoMetec A/S Maintains Earnings Guidance for the Year 2024ChemoMetec A/S maintained earnings guidance for the year 2024. The company maintain full-year guidance for 2023/24 of revenue in the range of DKK 400 million - DKK 435 million and EBITDA in the range of DKK 200 million - DKK 220 million.
공시 • Dec 21ChemoMetec A/S Announces Executive ChangesChemoMetec A/S announced that COO and deputy chairman of the board Martin Glensbjerg has decided to step down in ChemoMetec to pass the baton on to the next generation. From 1 February 2024 until the end of 2024, he will act as Senior Advisor with reference to CEO Rasmus Kofoed. Martin Glensbjerg continues as deputy chairman of the board. In his new role, Martin Glensbjerg will, among other things, participate in the update of ChemoMetec's strategy and also contribute to ensuring a successful anchoring and launch of the upcoming new products, including XcytoMatic 40 and XcytoMatic 30. At the same time, Martin Helbo Behrens, Deputy COO, is appointed COO, and Bo Melholt Nielsen, Physicist & Project Manager, Chief R&D Officer. Both Martin Helbo Behrens and Bo Melholt Nielsen have been employed at ChemoMetec for a number of years. Before joining as Deputy COO earlier this year, Martin Helbo Behrens was CFO and COO in ChemoMetec's American subsidiary and was part of Group Finance before that. Bo Melholt Nielsen has a strong academic and professional background in physics, especially quantum optics, and as project manager for the development of XcytoMatic 40 and XcytoMatic 30 he has been a significant driving force behind the development of the new generation of products. Martin Glensbjerg was one of three co-founders when ChemoMetec was established in 1997, and since then he has held a leading position in the company and has made a significant contribution to ensuring that ChemoMetec has achieved an attractive global market position.
Valuation Update With 7 Day Price Move • Dec 19Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €55.30, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 31x in the Life Sciences industry in Europe. Total loss to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €39.98 per share.
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 27%After last week's 27% share price gain to €43.46, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €41.87 per share.
Buying Opportunity • Oct 25Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 41%. The fair value is estimated to be €45.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 37%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 13% per annum over the same time period.
Valuation Update With 7 Day Price Move • Oct 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €45.84, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €44.40 per share.
Upcoming Dividend • Oct 06Upcoming dividend of kr.6.00 per share at 1.8% yieldEligible shareholders must have bought the stock before 13 October 2023. Payment date: 17 October 2023. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (5.0%). Higher than average of industry peers (0.9%).
공시 • Sep 14+ 1 more updateChemometec A/S Proposes Dividend for the 2022/23 Financial YearChemoMetec A/S proposed to the general meeting that a dividend of DKK 6.0 per share, equivalent to a total dividend payout of DKK 104.4 million, be distributed for the 2022/23 financial year. The proposal should be seen in the context of ChemoMetec’s strong financial position, and the planned investments in new facilities have also been taken into account.
Reported Earnings • Sep 14Full year 2023 earnings released: EPS: kr.10.27 (vs kr.9.16 in FY 2022)Full year 2023 results: EPS: kr.10.27 (up from kr.9.16 in FY 2022). Revenue: kr.444.4m (up 3.7% from FY 2022). Net income: kr.178.7m (up 12% from FY 2022). Profit margin: 40% (up from 37% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
New Risk • Aug 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (7.0% average weekly change).
공시 • Jun 28+ 4 more updatesChemoMetec A/S to Report Fiscal Year 2024 Results on Sep 11, 2024ChemoMetec A/S announced that they will report fiscal year 2024 results on Sep 11, 2024
공시 • May 10ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023ChemoMetec A/S affirmed earnings guidance for the fiscal year 2022/2023. For the year, based on developments in the third quarter of 2022/23, guidance for financial year 2022/23, as announced in connection with the release of the interim report for 2022/23 on 8 February 2023, is maintained. Accordingly, revenue for 2022/23 is expected in the range of DKK 430 million - DKK 460 million.
Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €52.90, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 36x in the Life Sciences industry in Europe. Total returns to shareholders of 29% over the past three years.
Valuation Update With 7 Day Price Move • Feb 15Investor sentiment deteriorates as stock falls 25%After last week's 25% share price decline to €66.20, the stock trades at a trailing P/E ratio of 48.1x. Average trailing P/E is 45x in the Life Sciences industry in Europe. Total returns to shareholders of 76% over the past three years.
Reported Earnings • Feb 10First half 2023 earnings released: EPS: kr.6.06 (vs kr.4.90 in 1H 2022)First half 2023 results: EPS: kr.6.06 (up from kr.4.90 in 1H 2022). Revenue: kr.242.7m (up 16% from 1H 2022). Net income: kr.105.4m (up 24% from 1H 2022). Profit margin: 43% (up from 41% in 1H 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 40% per year.
공시 • Feb 09ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023ChemoMetec A/S updated earnings guidance for the fiscal year 2022/2023. For the year, the company expected revenue of DKK 430 million - DKK 460 million, against the previous guidance of DKK 485 million-DKK 505 million.
Valuation Update With 7 Day Price Move • Dec 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €93.70, the stock trades at a trailing P/E ratio of 76.9x. Average trailing P/E is 42x in the Life Sciences industry in Europe. Total returns to shareholders of 267% over the past three years.
공시 • Dec 15Chemometec A/S Announces Resignation of Steen Søndergaard as CEOSteen Søndergaard has announced that he wants to resign from his position as CEO of ChemoMetec A/S. It has been agreed that Steen Søndergaard remains in his position until a replacement has been found, however with resignation during the calendar year 2023 and possibly no later than 30 June 2023. The search for a new CEO has been initiated, and the Board of Directors expects to announce the name of the new CEO during the first quarter of 2023.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Nov 08ChemoMetec A/S Provides Earnings Guidance for the Financial Year 2022-23ChemoMetec A/S provided earnings guidance for the financial year 2022-23. For the period, the company expects revenue to be in the range of DKK 485 million - DKK 505 million.
Valuation Update With 7 Day Price Move • Sep 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €79.50, the stock trades at a forward P/E ratio of 53x. Average forward P/E is 31x in the Life Sciences industry in Europe. Total returns to shareholders of 343% over the past three years.
Reported Earnings • Sep 17Full year 2022 earnings released: EPS: kr.9.16 (vs kr.5.08 in FY 2021)Full year 2022 results: EPS: kr.9.16 (up from kr.5.08 in FY 2021). Revenue: kr.428.4m (up 52% from FY 2021). Net income: kr.159.5m (up 81% from FY 2021). Profit margin: 37% (up from 31% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Sep 15ChemoMetec A/S Provides Revenue Guidance for the Fiscal Year 2023ChemoMetec A/S provided revenue guidance for the fiscal year 2023. For the period, the company expects revenue in the range of DKK 485 million - DKK 505 million.
공시 • Jul 16+ 6 more updatesChemoMetec A/S, Annual General Meeting, Oct 12, 2023ChemoMetec A/S, Annual General Meeting, Oct 12, 2023.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 10First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: EPS: kr.4.90 (up from kr.2.43 in 1H 2021). Revenue: kr.209.8m (up 58% from 1H 2021). Net income: kr.85.2m (up 101% from 1H 2021). Profit margin: 41% (up from 32% in 1H 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 67% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Oct 08Upcoming dividend of kr.4.00 per shareEligible shareholders must have bought the stock before 15 October 2021. Payment date: 19 October 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (0.4%).
Reported Earnings • Sep 18Full year 2021 earnings released: EPS kr.5.08 (vs kr.3.51 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: kr.281.1m (up 31% from FY 2020). Net income: kr.88.4m (up 49% from FY 2020). Profit margin: 31% (up from 28% in FY 2020). The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Feb 10New 90-day high: €80.40The company is up 48% from its price of €54.50 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 10.0% over the same period.
Reported Earnings • Feb 07First half 2021 earnings released: EPS kr.2.43 (vs kr.1.68 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: kr.133.0m (up 28% from 1H 2020). Net income: kr.42.3m (up 54% from 1H 2020). Profit margin: 32% (up from 27% in 1H 2020). The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Dec 31New 90-day high: €76.60The company is up 37% from its price of €55.90 on 02 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Dec 16New 90-day high: €66.30The company is up 23% from its price of €54.00 on 17 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Dec 01New 90-day high: €60.70The company is up 14% from its price of €53.10 on 02 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 1.0% over the same period.
Reported Earnings • Sep 19Full year earnings released - EPS €3.51Over the last 12 months the company has reported total profits of kr.59.2m, up 41% from the prior year. Total revenue was kr.214.1m over the last 12 months, up 22% from the prior year. Profit margins were 28%, which is higher than the 24% margin from last year. The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Sep 18New 90-day high: €54.00The company is up 26% from its price of €42.70 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 19% over the same period.